Exhibit 99.1

  Dr. Reddy’s Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel    :+91 40 4900 2900 Fax   :+91 40 4900 2999 Email :mail@drreddys.com www.drreddys.com

February 20, 2020

Corporate Relationship Department	National Stock Exchange of India Ltd.
BSE Limited	“Exchange Plaza”
Dalal Street, Fort	Bandra-Kurla Complex, Bandra (East),
Mumbai – 400 001	Mumbai – 400 051
Fax Nos.: 022-22723121 / 22723719 /	Fax Nos.: 022-26598120/ 26598237/
22722037 / 22722039	26598238
Scrip Code: 500124	Scrip Code: DRREDDY-EQ

Dear Sirs,

Sub: Intimation

Further to our intimations dated August 20, 2019 and February 16, 2020 with regard to the audit of our Formulations Manufacturing Plant (“Vizag SEZ Plant 1 - FTO 7”) at Duvvada, Visakhapatnam, we would like to inform you that we have received the Establishment Inspection Report (EIR) from US FDA, for the above-referred facility, indicating closure of the audit. As intimated earlier the facility has been classified as VAI (Voluntary Action Indicated)

This is for your information.

With regards,

/s/ Vikas Sabharwal

Vikas Sabharwal

Assistant Company Secretary

CC:- New York Stock Exchange Inc.(Stock Code :RDY)